Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLRB NASDAQ:GELS NASDAQ:HOWL NASDAQ:MDCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLRBCellectar Biosciences$2.23-0.9%$2.86$2.20▼$13.47$17.98M0.52192,184 shs66,121 shsGELSGelteq$0.99-35.3%$0.58$0.39▼$2.30$16.39M-0.27.71 million shs6.15 million shsHOWLWerewolf Therapeutics$0.38-3.3%$0.67$0.36▼$2.38$19.16M0.29543,266 shs420,396 shsMDCXMedicus Pharma$0.34+1.5%$0.34$0.25▼$3.69$18.86M0.142.30 million shs946,514 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLRBCellectar Biosciences-0.44%-18.18%-22.95%-29.69%-82.43%GELSGelteq+197.38%+197.67%+255.90%+96.15%-34.62%HOWLWerewolf Therapeutics+8.00%-8.33%-37.63%-49.45%-67.95%MDCXMedicus Pharma+4.00%-10.92%+5.62%-39.00%-87.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLRBCellectar Biosciences$2.23-0.9%$2.86$2.20▼$13.47$17.98M0.52192,184 shs66,121 shsGELSGelteq$0.99-35.3%$0.58$0.39▼$2.30$16.39M-0.27.71 million shs6.15 million shsHOWLWerewolf Therapeutics$0.38-3.3%$0.67$0.36▼$2.38$19.16M0.29543,266 shs420,396 shsMDCXMedicus Pharma$0.34+1.5%$0.34$0.25▼$3.69$18.86M0.142.30 million shs946,514 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLRBCellectar Biosciences-0.44%-18.18%-22.95%-29.69%-82.43%GELSGelteq+197.38%+197.67%+255.90%+96.15%-34.62%HOWLWerewolf Therapeutics+8.00%-8.33%-37.63%-49.45%-67.95%MDCXMedicus Pharma+4.00%-10.92%+5.62%-39.00%-87.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLRBCellectar Biosciences 2.50Moderate Buy$11.00393.27% UpsideGELSGelteq 1.00SellN/AN/AHOWLWerewolf Therapeutics 2.14Hold$3.75884.25% UpsideMDCXMedicus Pharma 2.25Hold$9.002,565.09% UpsideCurrent Analyst Ratings BreakdownLatest GELS, CLRB, MDCX, and HOWL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026GELSGelteq Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/15/2026CLRBCellectar Biosciences LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy5/7/2026GELSGelteq Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/5/2026CLRBCellectar Biosciences Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.004/22/2026GELSGelteq Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026MDCXMedicus Pharma Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/20/2026CLRBCellectar Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026HOWLWerewolf Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026MDCXMedicus Pharma D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.004/10/2026MDCXMedicus Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/19/2026MDCXMedicus Pharma D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLRBCellectar BiosciencesN/AN/AN/AN/A$1.89 per shareN/AGELSGelteq$110K96.39N/AN/A$1.08 per share0.92HOWLWerewolf Therapeutics$1.88M9.85N/AN/A$0.51 per share0.75MDCXMedicus PharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLRBCellectar Biosciences-$21.79M-$6.66N/AN/AN/AN/A-349.24%-153.18%8/13/2026 (Estimated)GELSGelteq-$4.30MN/AN/AN/AN/AN/AN/AN/AN/AHOWLWerewolf Therapeutics-$60.82M-$1.24N/AN/AN/AN/A-208.23%-75.12%8/13/2026 (Estimated)MDCXMedicus Pharma-$35.46M-$2.68N/AN/AN/AN/A-3,137.84%-311.33%8/10/2026 (Estimated)Latest GELS, CLRB, MDCX, and HOWL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CLRBCellectar Biosciences-$1.8850-$1.33+$0.5550-$1.33$8.00 millionN/A5/14/2026Q1 2026MDCXMedicus Pharma-$0.18-$0.31-$0.13-$0.31N/AN/A5/7/2026Q1 2026HOWLWerewolf Therapeutics-$0.32-$0.28+$0.04-$0.28N/AN/A3/27/2026Q4 2025HOWLWerewolf Therapeutics-$0.34-$0.20+$0.14-$0.20$0.30 millionN/A3/26/2026Q4 2025MDCXMedicus Pharma-$0.32-$0.82-$0.50-$0.83N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCLRBCellectar BiosciencesN/AN/AN/AN/AN/AGELSGelteqN/AN/AN/AN/AN/AHOWLWerewolf TherapeuticsN/AN/AN/AN/AN/AMDCXMedicus PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLRBCellectar BiosciencesN/A1.901.90GELSGelteqN/AN/AN/AHOWLWerewolf TherapeuticsN/A1.271.27MDCXMedicus PharmaN/A1.221.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLRBCellectar Biosciences16.41%GELSGelteqN/AHOWLWerewolf Therapeutics64.84%MDCXMedicus PharmaN/AInsider OwnershipCompanyInsider OwnershipCLRBCellectar Biosciences2.58%GELSGelteqN/AHOWLWerewolf Therapeutics23.60%MDCXMedicus Pharma8.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLRBCellectar Biosciences107.99 million7.79 millionNo DataGELSGelteqN/A10.71 millionN/AN/AHOWLWerewolf Therapeutics4048.60 million37.13 millionOptionableMDCXMedicus PharmaN/A56.66 million52.07 millionN/AGELS, CLRB, MDCX, and HOWL HeadlinesRecent News About These CompaniesMedicus Pharma Ltd: Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix in Endometriosis utilizing the Emirati Genome ProgramJune 11 at 6:30 PM | finanznachrichten.deMedicus Pharma files IND for genomics-enabled endometriosis trial in UAEJune 11 at 8:53 AM | proactiveinvestors.comMedicus Pharma Ltd. Submits IND Application for Innovative PRECISION-E2 Phase 2a Clinical Trial in EndometriosisJune 11 at 7:51 AM | quiverquant.comQMedicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome ProgramJune 11 at 7:30 AM | globenewswire.comMedicus Pharma Ltd: Medicus Pharma Advances Teverelix Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European ...June 8, 2026 | finanznachrichten.deMedicus Pharma submits EU clinical trial modification for prostate cancer drug TeverelixJune 8, 2026 | proactiveinvestors.comMedicus Pharma submits EU clinical trial modification for prostate cancer drug TeverelixJune 8, 2026 | proactiveinvestors.comMedicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European SubmissionJune 8, 2026 | globenewswire.comMedicus Pharma advances SkinJect toward registrational trial for rare Gorlin SyndromeJune 6, 2026 | finance.yahoo.comMedicus Pharma advances SkinJect for Gorlin syndrome – ICYMIJune 6, 2026 | proactiveinvestors.comMedicus Pharma advances SkinJect for Gorlin syndrome – ICYMIJune 6, 2026 | proactiveinvestors.comMedicus Pharma Shareholders Approve Auditor, Board and ConsolidationJune 4, 2026 | tipranks.comFTSE 100 Live: Stocks heading lower despite oil falling on Israel dealJune 4, 2026 | proactiveinvestors.comMedicus Pharma advances SkinJect program with FDA submission targeting Gorlin SyndromeJune 3, 2026 | proactiveinvestors.comMedicus Pharma Advances SkinJect® into Registrational Development for Gorlin SyndromeJune 3, 2026 | globenewswire.comMedicus Pharma Ltd: Medicus Pharma Announces $22 Million Non-Dilutive FinancingMay 28, 2026 | finanznachrichten.deMedicus Pharma secures up to $22M in non-dilutive financing facilityMay 28, 2026 | proactiveinvestors.comMedicus Pharma Announces $22 Million Non-Dilutive FinancingMay 28, 2026 | globenewswire.comMedicus Pharma Secures Financing Amid Nasdaq Compliance PressureMay 27, 2026 | tipranks.comMedicus Pharma Ltd. (MDCXW) Reports FDA Progress and Expands 2026 Clinical OutlookMay 19, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGELS, CLRB, MDCX, and HOWL Company DescriptionsCellectar Biosciences NASDAQ:CLRB$2.23 -0.02 (-0.89%) Closing price 04:00 PM EasternExtended Trading$2.24 +0.00 (+0.22%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Gelteq NASDAQ:GELS$0.99 -0.54 (-35.29%) Closing price 04:00 PM EasternExtended Trading$0.96 -0.03 (-2.53%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.Werewolf Therapeutics NASDAQ:HOWL$0.38 -0.01 (-3.35%) Closing price 04:00 PM EasternExtended Trading$0.40 +0.02 (+4.20%) As of 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.Medicus Pharma NASDAQ:MDCX$0.34 +0.00 (+1.47%) Closing price 04:00 PM EasternExtended Trading$0.34 0.00 (-0.50%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
